RATIONALE: Subcutaneous immune globulin 20%, Ig20Gly, was well tolerated in the phase 2/3 North American study in patients with primary immunodeficiency diseases (PIDD). Here we analyze the tolerability and onboarding experience with Ig20Gly infused at high rates and volumes in pediatric and advanced age patients (2-<16 y and > _60 y). METHODS: Patients aged > _2 years with PIDD received weekly Ig20Gly infusions at volumes < _60 mL/site and rates < _60 mL/h/site for ;1.3 years in the North American study (NCT01218438). Adverse events (AEs), tolerability, and infusion parameters were assessed in pediatric (n521) and advanced age patients (n514). RESULTS: Median maximum infusion rates and volumes/site were higher in advanced age patients (60 mL/h/site; 47.5 mL/site) versus pediatric patients (30 mL/h/site; 26.75 mL/site). Five (23.8%) pediatric patients and 9 (64.3%) advanced age patients used infusion rates > _60 mL/h/ site for > _2 infusions. Maximum infusion rates were not tried in the majority of pediatric patients given the smaller dose volumes used in these patients. ; none were serious or severe in either age group. Larger infusion volumes and faster infusion rates were not associated with an increase in causally related local AEs in either age group. CONCLUSIONS: Ig20Gly infused at relatively high rates and volumes was well tolerated in both pediatric and advanced age patients with PIDD.
350
Vasculitis as a major morbidity factor in patients with hypomorphic RAG mutations In a recent search of the USIDNet database, vasculitis was found to be an uncommon complication (1.6%), however associated with CVID (38%). (Byram K. et al. AAAI meeting 2019) We also reported that hypomorphic RAG deficiency may occur in 1 in 500 patients with antibody deficiency, including CVID. METHODS: The aim of this study was to establish the clinical, laboratory features and treatment outcome of vasculitis in RAG deficiency. In our cohort of 67 patients with hypomorphic RAG deficiency, we identified 7 patients (10.4%) with episodes of vasculitis. RESULTS: Median age was 5 years, with vasculitis occurred early in course of disease with a mean onset of 2 years compared to diagnosis of RAG deficiency with 3 years. Vasculitis was associate with a high mortality (5/7, 71%) and was complicated by significant end organ necrosis (n53), stroke (n51). Systemic vasculitis was refractory to first-or second-line therapy, including steroids and immunosuppression and required HSCT for definitive management. Although patients were mostly ANCA negative, anti-cytokine antibodies were detected in a large fraction of the cases (3/5, 60 %). Varicella or other viral infections preceded in the onset of disease in many of the patients (2/5, 40%). CONCLUSIONS: Our data suggest that vasculitis is a key component of morbidity among patients with hypomorphic RAG variants. Diagnostic serology may be misleading and may be extended to testing for anticytokine antibodies. Early escalated of treatment such as HSCT may improve therapeutic outcome. Evaluation for RAG deficiency should be considered among PID patients with antibody deficiency and vasculitis.
